Redeye tar upp Vicore Pharma till bevakning med fair value i basscenariot 21 SEK

Andreas Kvist, Life Science analyst at Redeye, has published his initial analysis of VICORE PHARMA. Read more and download the full report: https://goo.gl/6cSYnv

Become a member at Redeye in order to follow the company and get access to the latest analyses and updates.

This is a press release from Redeye - Research Powered Investment Banking. http://beta.redeye.se/